今日（9.12），沪指创阶段新高后小幅回调。市场震荡环境下，业绩相对稳健、估值性价比更高的品种或受资金关注。以兼具消费和医药属性的中药板块为 例，中药ETF（560080）收跌0.63%，全天成交额近1亿元，较昨日放量32%，场内持续溢价！资金面上，中药ETF（560080）已连续9日获资金青睐，累计净 流入超1.2亿元！融资余额亦连续攀升，中药ETF（560080）最新融资余额近7000万元！ 【中药ETF（560080）年初以来行情走势&成交额变化】 板块估值方面，中药板块动态市盈率居2021年以来低位。截至2025年9月11日，中证中药指数市盈率TTM为25.97x，仍在2021年以来低位。 中药ETF（560080）标的指数热门成分股多数飘绿，白云山、云南白药、以岭药业跌超1%，片仔癀、东阿阿胶、同仁堂、天士力微跌。上涨方面，众生药 业、达仁堂微涨。 | 序号 | 代码 | 名称 | 涨跌幅 | 估算权重 | | --- | --- | --- | --- | --- | | 1 | 600332 | XD日云山 | -1.56% | 4.19% | | 2 | 000538 | 云南日药 | -1. ...

Core Viewpoint - The Chinese medicine sector is experiencing significant growth, with the Zhongzheng Traditional Chinese Medicine Index and related ETFs showing strong performance, indicating a positive market sentiment towards traditional Chinese medicine companies [1][2][3]. Group 1: Market Performance - As of August 1, 2025, the Zhongzheng Traditional Chinese Medicine Index rose by 2.63%, with notable increases in constituent stocks such as Xintian Pharmaceutical (up 10.03%) and Tailong Pharmaceutical (up 10.00%) [1]. - The Zhongzheng Traditional Chinese Medicine ETF (560080) increased by 3.06%, reaching a latest price of 1.15 yuan, and has seen a cumulative increase of 2.58% over the past two weeks [1]. - The trading volume for the Zhongzheng Traditional Chinese Medicine ETF was 59.73 million yuan, with a turnover rate of 3.02% [1]. Group 2: Fund Growth - The Zhongzheng Traditional Chinese Medicine ETF experienced a significant scale increase of 57.84 million yuan over the past week, ranking first among comparable funds [2]. - The ETF's share count grew by 31.50 million shares in the same period, also placing it at the top among comparable funds [3]. Group 3: Capital Flow - The latest net capital outflow for the Zhongzheng Traditional Chinese Medicine ETF was 14.52 million yuan, but there was a net inflow of 43.60 million yuan over the last five trading days, averaging 8.72 million yuan per day [4]. - Leverage funds are increasingly investing in the ETF, with the latest margin buying amounting to 6.77 million yuan and a margin balance of 52.14 million yuan [4]. Group 4: Industry Developments - Tongrentang Group's healthcare segment "Tongrentang Medical Care" successfully listed on the Hong Kong Stock Exchange, marking its fourth company listed in Hong Kong, focusing on integrated medical services [4]. - The company aims to acquire five medical institutions and upgrade systems with the funds raised, projecting revenues between 911 million and 1.175 billion yuan from 2022 to 2024 [4]. Group 5: Regulatory Environment - A nationwide initiative is underway to regulate the pricing of traditional Chinese medicine, addressing issues of inflated prices for commonly used products [5]. - The ongoing centralized procurement of traditional Chinese medicine is expected to expand, affecting 20%-30% of the market, which may lead to increased brand concentration in the retail market [5].